Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05119179 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

StatusRecruiting
PhasePhase 4
Started2021-11-22
View on ClinicalTrials.gov ↗

Amendment history

2026-03-13
Study Status v5
Primary completion date2025-11→2026-10-31
Completion date2026-07→2026-10-31
2024-12-05
Study Identification, Study Status, Sponsor/Collaborators v4
Collaborators1 to 2 entries
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2023-06-08
Study Status v3
Primary completion date2025-12→2025-11
2023-05-11
Study Status, Oversight v2
Primary completion date2025-11→2025-12
2022-03-15
Study Status v1
Start dateestimated 2021-11-15→confirmed 2021-11-22
2021-11-01
Original filing
This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obesity, cardiovascular disease, renal disease, and other related diseases.
Trial Details
NCT Number NCT05119179
Lead Sponsor The University of Texas Health Science Center, Houston
Collaborators: Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions PreDiabetes
Enrollment 300 participants
Start Date 2021-11-22
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-17